



Contents lists available at ScienceDirect

Biochemical and Biophysical Research Communications

journal homepage: [www.elsevier.com/locate/ybbrc](http://www.elsevier.com/locate/ybbrc)

## Mutant $\gamma$ PKC that causes spinocerebellar ataxia type 14 upregulates Hsp70, which protects cells from the mutant's cytotoxicity

Kota Ogawa<sup>a,1</sup>, Takahiro Seki<sup>a,b,1</sup>, Tomoya Onji<sup>a</sup>, Naoko Adachi<sup>c</sup>, Shigeru Tanaka<sup>a</sup>, Izumi Hide<sup>a</sup>, Naoaki Saito<sup>c</sup>, Norio Sakai<sup>a,\*</sup>

<sup>a</sup> Department of Molecular and Pharmacological Neuroscience, Institute of Biomedical & Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan

<sup>b</sup> Department of Chemico-Pharmacological Sciences, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto 862-0973, Japan

<sup>c</sup> Laboratory of Molecular Pharmacology, Biosignal Research Center, Kobe University, Kobe 657-8501, Japan

### ARTICLE INFO

#### Article history:

Received 22 August 2013

Available online xxxxx

#### Keywords:

$\gamma$ PKC  
Spinocerebellar ataxia  
Heat-shock protein 70  
Aggregation  
Cytotoxicity

### ABSTRACT

Several missense mutations in the protein kinase C $\gamma$  ( $\gamma$ PKC) gene have been found to cause spinocerebellar ataxia type 14 (SCA14), an autosomal dominant neurodegenerative disease. We previously demonstrated that the mutant  $\gamma$ PKC found in SCA14 is misfolded, susceptible to aggregation and cytotoxic. Molecular chaperones assist the refolding and degradation of misfolded proteins and prevention of the proteins' aggregation. In the present study, we found that the expression of mutant  $\gamma$ PKC-GFP increased the levels of heat-shock protein 70 (Hsp70) in SH-SY5Y cells. To elucidate the role of this elevation, we investigated the effect of siRNA-mediated knockdown of Hsp70 on the aggregation and cytotoxicity of mutant  $\gamma$ PKC. Knockdown of Hsp70 exacerbated the aggregation and cytotoxicity of mutant  $\gamma$ PKC-GFP by inhibiting this mutant's degradation. These findings suggest that mutant  $\gamma$ PKC increases the level of Hsp70, which protects cells from the mutant's cytotoxicity by enhancing its degradation.

© 2013 Elsevier Inc. All rights reserved.

### 1. Introduction

Spinocerebellar ataxia type 14 (SCA14) is an autosomal dominant spinocerebellar ataxia that is clinically characterized by slowly progressive cerebellar ataxia and caused by missense or deletion mutations in the *PRKCG* gene, which encodes protein kinase C $\gamma$  ( $\gamma$ PKC) [1,2].  $\gamma$ PKC is a neuron-specific isoform of PKC that is especially abundant in cerebellar Purkinje cells (PCs) [3]. We have previously demonstrated that missense mutations of  $\gamma$ PKC make this protein prone to aggregation in cultured cell lines and primary cultured PCs [4–7]. The accumulation of misfolded proteins is a common feature of various neurodegenerative diseases, including Alzheimer's, Parkinson's and polyglutamine diseases [8,9]. Therefore, SCA14 is caused by a mechanism common to other neurodegenerative disorders.

**Abbreviations:**  $\gamma$ PKC, protein kinase C $\gamma$ ; SCA14, spinocerebellar ataxia type 14; Hsp70, heat-shock protein 70; Hsp40, heat-shock protein 40; Hsp90, heat-shock protein 90; GFP, green fluorescent protein; PCs, Purkinje cells; WT, wild-type; LDH, lactate dehydrogenase; CHIP, carboxyl terminus of Hsp70-interacting protein; JNK, c-Jun N-terminal kinase; Hsc70, heat-shock cognate protein 70; 17-AAG, 17-allylamino-17-demethoxygeldanamycin.

\* Corresponding author. Address: Department of Molecular and Pharmacological Neuroscience, Institute of Biomedical & Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8551, Japan. Fax: +81 82 257 5144.

E-mail address: [nsakai@hiroshima-u.ac.jp](mailto:nsakai@hiroshima-u.ac.jp) (N. Sakai).

<sup>1</sup> These authors contributed equally to this work.

Molecular chaperones are proteins that assist protein folding during synthesis and that stabilize misfolded proteins generated by various stresses, such as heat shock [10]. There are several reports demonstrating that molecular chaperones accumulate in inclusions of misfolded proteins in patient tissues and cellular models of neurodegenerative diseases [11,12]. In addition, the overexpression of molecular chaperones alleviates aggregate formation, neurodegeneration and neuropathological functions in model animals of neurodegenerative diseases [13,14]. In the present study, we focused on the effects of SCA14 mutant  $\gamma$ PKC on the levels and distributions of molecular chaperones. Mutant  $\gamma$ PKC significantly elevated the level of heat-shock protein 70 (Hsp70) in the presence or absence of aggregation. siRNA-mediated knockdown revealed that the induction of Hsp70 protected cells from the toxicity of mutant  $\gamma$ PKC by enhancing the mutant's degradation. These findings suggest that Hsp70 could be a novel therapeutic target in SCA14.

### 2. Materials and methods

#### 2.1. Materials

Dulbecco's modified Eagle's medium (DMEM), Alexa Fluor 546-conjugated anti-mouse IgG antibody and Alexa Fluor 350-conjugated anti-rabbit IgG antibody were obtained from Life Technologies (Carlsbad, CA, USA). The MISSION siRNA universal

negative control and anti- $\beta$ -tubulin 1 antibody were from Sigma Aldrich (St. Louis, MO, USA). Anti-Hsp40, anti-Hsp70 and anti-Hsp90 antibodies were from Enzo Life Sciences (Farmingdale, NY, USA). Anti-GFP antibody, Ham's F-12 medium and penicillin/streptomycin solution were from Nacalai Tesque (Kyoto, Japan). Anti-calbindin antibody was from Millipore (Billerica, MA). Hsp70 siRNA (sense: 5'-GAACCAGGUGGCGCUGAACdTdT-3', antisense: 5'-GUUCAGCGCCACCUUGUUCdTdT-3' [15]) was synthesized by Hayashi Kasei (Osaka, Japan). Horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG and anti-rabbit IgG antibodies were from Jackson ImmunoResearch Laboratories (West Grove, PA, USA). Glass-bottomed culture dishes (35-mm diameter) were from MatTek (Ashland, MA, USA). The Nerve-Cell Culture System (neuron culture medium and dissociation solutions) was from Sumitomo Bakelite (Tokyo, Japan).

## 2.2. Cell culture

SH-SY5Y cells were cultured in a DMEM/F-12 mixture (1:1) supplemented with 10% fetal bovine serum (FBS), 100 units/ml penicillin and 100 g/ml streptomycin in a humidified atmosphere containing 5% CO<sub>2</sub> at 37 °C. A mouse cerebellar primary culture was prepared as described previously [5]. Briefly, E14 embryos from pregnant ICR mice were dissociated using the dissociation solutions of the Sumitomo Nerve-Cell Culture System according to the manufacturer's protocol. Dissociated cerebellar cells were suspended in the neuron culture medium of the same system on a 35-mm diameter glass-bottomed culture dish. Cells were cultured for 28 days in vitro (DIV) in a humidified atmosphere containing 5% CO<sub>2</sub> at 37 °C.

## 2.3. Transfection of $\gamma$ PKC-GFP and siRNA

$\gamma$ PKC-GFP (wild-type (WT) and S119P and G128D mutants) was expressed via adenoviral vectors using a tetracycline-regulated

system, as described previously [16]. SH-SY5Y cells were transfected with siRNA using Lipofectamine RNAiMAX (Invitrogen) during cell spreading. Two adenoviral vectors (Ad-CMV-tTA and Ad-TetOp- $\gamma$ PKC-GFP) were used for infection 1 day after cell spreading. For dissociated cerebellar culture, two adenoviral vectors (Ad-L7-tTA and Ad-TetOp- $\gamma$ PKC-GFP) were used for infection at DIV14 to selectively express  $\gamma$ PKC-GFP in PCs.


## 2.4. Immunoblotting and immunostaining

The amounts of  $\gamma$ PKC-GFP, Hsp40, Hsp70 and Hsp90 were assessed by immunoblotting cell lysates from SH-SY5Y cells expressing WT or mutant  $\gamma$ PKC-GFP, as described previously [16]. Cells were harvested 2 days after adenoviral transfection. The degradation of  $\gamma$ PKC-GFP was analyzed by a chase assay after the arrest of gene expression by tetracycline treatment [17] beginning 1 day after transfection. The cells were harvested before (0 h) or after 24 h treatment with tetracycline (1  $\mu$ g/ml), followed by immunoblotting with anti-GFP antibody. All blots were probed with anti- $\beta$ -tubulin antibody as an internal control.

SH-SY5Y cells on glass-bottomed dishes were fixed with 4% paraformaldehyde, followed by immunostaining with anti-Hsp70 mouse monoclonal antibody and Alexa Fluor 546-conjugated anti-mouse IgG antibody [18]. Primary cultured cerebellar cells were immunostained with anti-calbindin antibody and Alexa Fluor 350-conjugated anti-rabbit antibody to identify PCs, in addition to Hsp70 immunostaining. Images of GFP and Alexa Fluor 546 fluorescence were captured using a confocal microscope (LSM510META, Carl Zeiss, Oberkochen, Germany).

## 2.5. Cytotoxicity assay

One day after siRNA transfection, SH-SY5Y cells were infected with adenoviral vectors to induce  $\gamma$ PKC-GFP expression. After further 2-day cultivation, the cytotoxicity of the  $\gamma$ PKC-GFP-expressing



**Fig. 1.** SCA14 mutant  $\gamma$ PKC-GFP upregulated Hsp70, but not Hsp40 and Hsp90. (A) Amount of  $\gamma$ PKC-GFP, Hsp40, Hsp70 and Hsp90 in SH-SY5Y cells expressing WT or mutant (S119P or G128D)  $\gamma$ PKC-GFP, as detected by immunoblotting. (B–D) Quantitative analyses of immunoblotting results for  $\gamma$ PKC-GFP (B), Hsp40 (C), Hsp70 (D) and Hsp90 (E). The amount of each protein was normalized to the amount of  $\beta$ -tubulin in the same blot. Mean values from five independent experiments are shown. Error bars, SE. \* $p < 0.01$ , \*\* $p < 0.001$  vs cells expressing WT  $\gamma$ PKC-GFP (unpaired  $t$ -test).

cells was assessed by a lactate dehydrogenase (LDH) assay using the CytoTox 96 NonRadioactive Cytotoxicity Assay (Promega, Fitchburg, WI, USA) according to the manufacturer's protocol.

### 3. Results


#### 3.1. SCA14 mutant $\gamma$ PKC upregulates Hsp70

To examine whether SCA14 mutant  $\gamma$ PKC affects the levels of molecular chaperones, the amounts of Hsp40, Hsp70 and Hsp90 were assessed by immunoblotting in SH-SY5Y cells expressing wild-type (WT) or missense mutant  $\gamma$ PKC-GFP (Fig. 1A). There was no significant difference between the amounts of expressed WT and mutant  $\gamma$ PKC-GFP (Fig. 1B). The amount of Hsp70 was significantly elevated in cells expressing mutant  $\gamma$ PKC-GFP (Fig. 1D), whereas Hsp40 and Hsp90 levels were slightly increased, but these increases were not significant (Fig. 1C and E). We have previously demonstrated that mutant  $\gamma$ PKC-GFP tends to form aggregates [4]. In various neurodegenerative diseases, molecular chaperones are reported to accumulate in neural inclusions [11,12]. Therefore, the distribution of Hsp70 was examined by immunostaining in cells expressing WT or


mutant  $\gamma$ PKC-GFP. As we reported previously, mutant  $\gamma$ PKC-GFP tended to form aggregates, whereas WT  $\gamma$ PKC-GFP was diffusely expressed in the cytoplasm (Fig. 2A). Consistent with immunoblotting results, the immunoreactivity of Hsp70 was elevated in cells expressing mutant  $\gamma$ PKC-GFP (Fig. 2A). Unexpectedly, this elevation was observed in many cells without aggregates of mutant  $\gamma$ PKC-GFP, in addition to strong colocalization of Hsp70 immunoreactivity to the mutant's aggregates (Fig. 2A). This elevation of Hsp70 expression was also observed in primary cultured PCs expressing mutant  $\gamma$ PKC-GFP (Fig. 2B). These results indicate that Hsp70 is upregulated in cells expressing mutant  $\gamma$ PKC independently of the mutant's aggregation.

#### 3.2. Hsp70 is elevated to degrade mutant $\gamma$ PKC, protecting cells from the mutant's toxicity

To explore the role of Hsp70 upregulation, we attempted to knock down Hsp70 using siRNA in cells expressing mutant  $\gamma$ PKC-GFP. siRNA against Hsp70 successfully decreased the level of Hsp70 compared with control siRNA-transfected cells (Fig. 3A and B). siRNA-mediated knockdown of Hsp70 significantly increased mutant  $\gamma$ PKC-GFP levels (Fig. 3A and C). To elucidate the



**Fig. 2.** Mutant  $\gamma$ PKC-GFP upregulated Hsp70 in the presence or absence of the mutant's aggregation. (A) Hsp70 immunostaining of SH-SY5Y cells expressing WT or mutant (S119P or G128D)  $\gamma$ PKC-GFP. Hsp70 strongly colocalized to aggregates of mutant  $\gamma$ PKC-GFP, although Hsp70 levels also increased in cells without aggregation of mutant  $\gamma$ PKC-GFP. Scale bar, 20  $\mu$ m. (B) Hsp70 and calbindin immunostaining of primary cultured cerebellar PCs expressing WT or mutant (S119P)  $\gamma$ PKC-GFP. The Hsp70 levels of PCs expressing WT  $\gamma$ PKC-GFP (arrowheads) were similar to levels in non-expressing PCs (arrowhead). In contrast, Hsp70 immunoreactivity was obviously increased in PCs expressing mutant  $\gamma$ PKC-GFP (arrows). Scale bar, 20  $\mu$ m.



**Fig. 3.** Knockdown of Hsp70 increased mutant  $\gamma$ PKC-GFP levels by inhibiting the mutant's degradation. (A) Amount of  $\gamma$ PKC-GFP and Hsp70 in  $\gamma$ PKC-GFP-expressing SH-SY5Y cells transfected with negative control (Cont or C) or Hsp70 (H) siRNA, as detected by immunoblotting. (B and C) Quantitative analyses of immunoblotting results for  $\gamma$ PKC-GFP (B) and Hsp70 (C). The amount of each protein was normalized to the amount of  $\beta$ -tubulin in the same blot. Mean values from three independent experiments are shown. Error bars, SE. \* $p < 0.05$  (unpaired  $t$ -test). (D) The degradation of WT and mutant (S119P)  $\gamma$ PKC-GFP was determined by a chase assay in cells transfected with control or Hsp70 siRNA. The expression of  $\gamma$ PKC-GFP was arrested by treatment with 1  $\mu$ g/ml tetracycline (Tet). Cells were harvested before (0 h) or 24 h after Tet treatment, followed by immunoblotting with anti-GFP and anti- $\beta$ -tubulin antibodies. (E) The degradation of  $\gamma$ PKC-GFP was quantitatively evaluated based on the amount of  $\gamma$ PKC-GFP at 24 h divided by the amount of  $\gamma$ PKC-GFP at 0 h. Mean values from four independent experiments are shown. Error bars, SE. \* $p < 0.05$  (paired  $t$ -test).


mechanism of how Hsp70 knockdown elevates the  $\gamma$ PKC-GFP level, we examined the degradation rate of  $\gamma$ PKC-GFP by gene arrest by tetracycline treatment [17]. Hsp70 knockdown slightly but significantly inhibited the degradation of mutant  $\gamma$ PKC-GFP (Fig. 3D and E). Next, we examined whether the aggregation and cytotoxicity of mutant  $\gamma$ PKC is affected by Hsp70 knockdown. siRNA against Hsp70 significantly exacerbated the aggregation of mutant  $\gamma$ PKC-GFP (Fig. 4A and B). An LDH assay revealed that this siRNA did not affect cytotoxicity to cells expressing WT  $\gamma$ PKC-GFP (Fig. 4C). As we previously reported, mutant  $\gamma$ PKC-GFP significantly increased the cytotoxicity, and this toxicity was significantly exacerbated by siRNA-mediated knockdown of Hsp70 (Fig. 4C). These findings suggest that Hsp70 is upregulated to enhance the degradation of mutant  $\gamma$ PKC, protecting cells from the mutant's toxicity.

#### 4. Discussion

In the present study, we found that the SCA14 missense mutant  $\gamma$ PKC induced the upregulation of Hsp70 in cultured cell lines and primary cultured PCs (Figs. 1 and 2). Consistent with its behavior in other neurodegenerative diseases [11,12], Hsp70 strongly colocalized to aggregates of mutant  $\gamma$ PKC. Because the overexpression of molecular chaperones reduces the aggregation of mutant proteins [13,14], chaperones would stabilize the misfolded proteins to prevent their aggregation. In the case of mutant  $\gamma$ PKC, the Hsp70 level was also increased in cells without any aggregates (Fig. 2). We have previously demonstrated that mutant  $\gamma$ PKC forms oligomers in cells [5]. Accumulating evidence suggests that oligomers of mutant protein have higher toxicity than do aggregates [19,20]. Hsp70

might prevent the oligomerization of mutant  $\gamma$ PKC in cells without aggregation.

siRNA-mediated knockdown of Hsp70 strengthened the notion that the Hsp70 level increased to protect cells from the toxicity of mutant  $\gamma$ PKC. Because Hsp70 knockdown significantly reduced the rate of mutant  $\gamma$ PKC degradation, Hsp70 may have a role in degrading mutant  $\gamma$ PKC (Fig. 3). We have previously demonstrated that mutant  $\gamma$ PKC is degraded more rapidly than the wild-type protein via both proteasomal and lysosomal pathways [17]. Although we did not determine which pathways are involved in the Hsp70-mediated degradation of mutant  $\gamma$ PKC, Hsp70 is known to participate in both of these protein degradation pathways. Regarding the proteasomal pathway, it is known that carboxyl terminus of Hsp70-interacting protein (CHIP), an E3 ubiquitin ligase, interacts with Hsp70 and ubiquitinates Hsp70 client proteins, leading to their degradation via the proteasome [21]. CHIP is reported to be involved in the degradation of many causal proteins of neurodegenerative diseases [22]. Therefore, it is possible that mutant  $\gamma$ PKC is also regulated by CHIP and that knockdown of Hsp70 prevents CHIP from detecting and ubiquitinating mutant  $\gamma$ PKC. Regarding the lysosomal proteolytic pathways, Hsp70 enhances macroautophagy, one type of lysosomal protein degradation, via c-Jun N-terminal kinase (JNK) pathways [23]. In addition, Hsp70 is known to interact with heat shock cognate protein 70 (Hsc70) [24], which is mainly involved in chaperone-mediated autophagy, another type of lysosomal protein degradation [25]. Therefore, Hsp70 might also affect chaperone-mediated autophagy. Furthermore, a small-molecule inhibitor of Hsp70 inhibits both proteasome-mediated and lysosome-mediated protein degradation [26]. Thus, Hsp70 may render the rapid degradation of mutant  $\gamma$ PKC



**Fig. 4.** Knockdown of Hsp70 exacerbated the aggregation and cytotoxicity of mutant  $\gamma$ PKC-GFP. (A) Aggregate formation in cells expressing mutant (S119P)  $\gamma$ PKC-GFP with control (upper) or Hsp70 (lower) siRNA. Scale bar, 20  $\mu$ m. (B) Quantification analyses of the aggregation. Mean values from three independent experiments are shown. Error bars, SE. \* $p < 0.05$  (paired  $t$ -test). (C) An LDH assay was conducted to evaluate cytotoxicity to WT or mutant (S119P)  $\gamma$ PKC-GFP-expressing cells transfected with control (C) or Hsp70 siRNA. Mean values from four independent experiments are shown. Error bars, SE. \* $p < 0.05$ , \*\* $p < 0.01$  (paired  $t$ -test).

via these two degradation pathways. Moreover, Hsp70 can stabilize lysosomal membranes, resulting in the protection of cells from apoptosis by lysosomal rupture [27]. This property of Hsp70 might contribute to its protective effect against the cytotoxicity of mutant  $\gamma$ PKC.

Our present findings indicate novel roles for Hsp70, which is upregulated by SCA14 mutant  $\gamma$ PKC, in therapeutic strategies for treating neurodegenerative disease. Inhibitors of Hsp90 (17-allylamino-17-demethoxygeldanamycin (17-AAG) and celastrol) are reported to increase the levels of molecular chaperones, including Hsp70 [28,29]. These chemicals have been demonstrated to have the potential to inhibit aggregation and prevent neurodegeneration in several neurodegenerative disease models [30–33]. Our present findings strongly suggest that these chemicals have potential as novel therapeutics for SCA14.

#### Acknowledgments

This study was supported by a Grant-in-Aid for Scientific Research from the Ministry of Education, Sports and Culture and by grants from the Takeda Science Foundation, the Uehara Memorial Foundation, the Naito Foundation, Suzuken Memorial Foundation, the Tokyo Biochemical Research Foundation and the Japanese Smoking Research Association.

#### References

- [1] D.H. Chen, P.J. Cimino, L.P. Ranum, H.Y. Zoghbi, I. Yabe, L. Schut, R.L. Margolis, H.P. Lipe, A. Feleke, M. Matsushita, J. Wolff, C. Morgan, D. Lau, M. Fernandez, H. Sasaki, W.H. Raskind, T.D. Bird, The clinical and genetic spectrum of spinocerebellar ataxia 14, *Neurology* 64 (2005) 1258–1260.
- [2] D.H. Chen, W.H. Raskind, T.D. Bird, Spinocerebellar ataxia type 14, *Handb. Clin. Neurol.* 103 (2012) 555–559.
- [3] N. Saito, U. Kikkawa, Y. Nishizuka, C. Tanaka, Distribution of protein kinase C-like immunoreactive neurons in rat brain, *J. Neurosci.* 8 (1988) 369–382.
- [4] T. Seki, N. Adachi, Y. Ono, H. Mochizuki, K. Hiramoto, T. Amano, H. Matsubayashi, M. Matsumoto, H. Kawakami, N. Saito, N. Sakai, Mutant protein kinase Cgamma found in spinocerebellar ataxia type 14 is susceptible to aggregation and causes cell death, *J. Biol. Chem.* 280 (2005) 29096–29106.
- [5] T. Seki, T. Shimahara, K. Yamamoto, N. Abe, T. Amano, N. Adachi, H. Takahashi, K. Kashiwagi, N. Saito, N. Sakai, Mutant gammaPKC found in spinocerebellar ataxia type 14 induces aggregate-independent maldevelopment of dendrites in primary cultured Purkinje cells, *Neurobiol. Dis.* 33 (2009) 260–273.
- [6] T. Seki, N. Adachi, N. Abe-Seki, T. Shimahara, H. Takahashi, K. Yamamoto, N. Saito, N. Sakai, Elucidation of the molecular mechanism and exploration of novel therapeutics for spinocerebellar ataxia caused by mutant protein kinase Cgamma, *J. Pharmacol. Sci.* 116 (2011) 239–247.
- [7] N. Sakai, N. Saito, T. Seki, Molecular pathophysiology of neurodegenerative disease caused by gammaPKC mutations, *World J. Biol. Psychiatry* 12 (Suppl. 1) (2011) 95–98.
- [8] J.P. Taylor, J. Hardy, K.H. Fischbeck, Toxic proteins in neurodegenerative disease, *Science* 296 (2002) 1991–1995.
- [9] C.A. Ross, M.A. Poirier, Protein aggregation and neurodegenerative disease, *Nat. Med.* 10 (Suppl) (2004) S10–7.
- [10] C. Burel, V. Mezger, M. Pinto, M. Rallu, S. Trigon, M. Morange, Mammalian heat shock protein families. Expression and functions, *Experientia* 48 (1992) 629–634.
- [11] C.J. Cummings, M.A. Mancini, B. Antalffy, D.B. DeFranco, H.T. Orr, H.Y. Zoghbi, Chaperone suppression of aggregation and altered subcellular proteasome localization imply protein misfolding in SCA1, *Nat. Genet.* 19 (1998) 148–154.
- [12] Y. Chai, S.L. Koppenhafer, N.M. Bonini, H.L. Paulson, Analysis of the role of heat shock protein (Hsp) molecular chaperones in polyglutamine disease, *J. Neurosci.* 19 (1999) 10338–10347.
- [13] J.M. Warrick, H.Y. Chan, G.L. Gray-Board, Y. Chai, H.L. Paulson, N.M. Bonini, Suppression of polyglutamine-mediated neurodegeneration in *Drosophila* by the molecular chaperone HSP70, *Nat. Genet.* 23 (1999) 425–428.
- [14] C.J. Cummings, Y. Sun, P. Opal, B. Antalffy, R. Mestriil, H.T. Orr, W.H. Dillmann, H.Y. Zoghbi, Over-expression of inducible HSP70 chaperone suppresses neuropathology and improves motor function in SCA1 mice, *Hum. Mol. Genet.* 10 (2001) 1511–1518.
- [15] J. Ishibashi, K. Yamashita, T. Ishikawa, H. Hosokawa, K. Sumida, M. Nagayama, S. Kitamura, The effects inhibiting the proliferation of cancer cells by far-infrared radiation (FIR) are controlled by the basal expression level of heat shock protein (HSP) 70A, *Med. Oncol.* 25 (2008) 229–237.

- [16] T. Seki, N. Abe-Seki, T. Kikawada, H. Takahashi, K. Yamamoto, N. Adachi, S. Tanaka, I. Hide, N. Saito, N. Sakai, Effect of trehalose on the properties of mutant  $\gamma$ PKC, which causes spinocerebellar ataxia type 14, in neuronal cell lines and cultured Purkinje cells, *J. Biol. Chem.* 285 (2010) 33252–33264.
- [17] K. Yamamoto, T. Seki, N. Adachi, T. Takahashi, S. Tanaka, I. Hide, N. Saito, N. Sakai, Mutant protein kinase C gamma that causes spinocerebellar ataxia type 14 (SCA14) is selectively degraded by autophagy, *Genes Cells* 15 (2010) 425–438.
- [18] T. Seki, K.I. Yoshino, S. Tanaka, E. Dohi, T. Onji, K. Yamamoto, I. Hide, H.L. Paulson, N. Saito, N. Sakai, Establishment of a novel fluorescence-based method to evaluate chaperone-mediated autophagy in a single neuron, *PLoS ONE* 7 (2012) e31232.
- [19] E.I. Agorogiannis, G.I. Agorogiannis, A. Papadimitriou, G.M. Hadjigeorgiou, Protein misfolding in neurodegenerative diseases, *Neuropathol. Appl. Neurobiol.* 30 (2004) 215–224.
- [20] H.C. Ardley, C.C. Hung, P.A. Robinson, The aggravating role of the ubiquitin-proteasome system in neurodegeneration, *FEBS Lett.* 579 (2005) 571–576.
- [21] S. Murata, T. Chiba, K. Tanaka, CHIP: a quality-control E3 ligase collaborating with molecular chaperones, *Int. J. Biochem. Cell Biol.* 35 (2003) 572–578.
- [22] C.A. Dickey, C. Patterson, D. Dickson, L. Petrucelli, Brain CHIP: removing the culprits in neurodegenerative disease, *Trends Mol. Med.* 13 (2007) 32–38.
- [23] S. Li, Y. Zhou, J. Fan, S. Cao, T. Cao, F. Huang, S. Zhuang, Y. Wang, X. Yu, H. Mao, Heat shock protein 72 enhances autophagy as a protective mechanism in lipopolysaccharide-induced peritonitis in rats, *Am. J. Pathol.* 179 (2011) 2822–2834.
- [24] R. Steel, R.S. Cross, S.L. Ellis, R.L. Anderson, Hsp70 architecture: the formation of novel polymeric structures of Hsp70.1 and Hsc70 after proteotoxic stress, *PLoS ONE* 7 (2013) e52351.
- [25] S.J. Orenstein, A.M. Cuervo, Chaperone-mediated autophagy: molecular mechanisms and physiological relevance, *Semin. Cell Dev. Biol.* 21 (2010) 719–726.
- [26] J.J. Leu, J. Pimkina, P. Pandey, M.E. Murphy, D.L. George, HSP70 inhibition by the small-molecule 2-phenylethanesulfonamide impairs protein clearance pathways in tumor cells, *Mol. Cancer Res.* 9 (2011) 936–947.
- [27] J. Nylandsted, M. Gyrd-Hansen, A. Danielewicz, N. Fehrenbacher, U. Lademann, M. Hoyer-Hansen, E. Weber, G. Multhoff, M. Rohde, M. Jaattela, Heat shock protein 70 promotes cell survival by inhibiting lysosomal membrane permeabilization, *J. Exp. Med.* 200 (2004) 425–435.
- [28] T.W. Schulte, L.M. Neckers, The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin, *Cancer Chemother. Pharmacol.* 42 (1998) 273–279.
- [29] A.M. Chow, I.R. Brown, Induction of heat shock proteins in differentiated human and rodent neurons by celastrol, *Cell Stress Chaperones* 12 (2007) 237–244.
- [30] M. Waza, H. Adachi, M. Katsuno, M. Minamiyama, C. Sang, F. Tanaka, A. Inukai, M. Doyu, G. Sobue, 17-AAG, an Hsp90 inhibitor, ameliorates polyglutamine-mediated motor neuron degeneration, *Nat. Med.* 11 (2005) 1088–1095.
- [31] M. Riedel, O. Goldbaum, L. Schwarz, S. Schmitt, C. Richter-Landsberg, 17-AAG induces cytoplasmic alpha-synuclein aggregate clearance by induction of autophagy, *PLoS ONE* 5 (2010) e8753.
- [32] C. Cleren, N.Y. Calingasan, J. Chen, M.F. Beal, Celastrol protects against MPTP- and 3-nitropropionic acid-induced neurotoxicity, *J. Neurochem.* 94 (2005) 995–1004.
- [33] Y.Q. Zhang, K.D. Sarge, Celastrol inhibits polyglutamine aggregation and toxicity though induction of the heat shock response, *J. Mol. Med. (Berl.)* 85 (2007) 1421–1428.